By Ian Walker
AstraZeneca PLC said Tuesday that the European Commission has conditionally approved Koselugo in the European Union for children with neurofibromatosis type 1 and plexiform neurofibromas.
The pharmaceutical giant said that Koselugo reduced tumor volume, pain and improved life quality in a Sprint Phase 2 trial.
Neurofibromatosis type 1 is a rare and debilitating genetic condition affecting one in 3,000 individuals world-wide.
Koselugo is already approved in the U.S. and several other countries for the treatment of pediatric patients with NF1 and symptomatic, inoperable plexiform neurofibromas.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
06-22-21 0229ET